Regeneron Pharmaceuticals Inc

NASDAQ: REGN
$1,139.00
-$11.20 (-1.0%)
Real Time Data Delayed 15 Min.

REGN Articles

These 10 stocks have incredibly strong stock charts and strong performance despite the crummy market conditions that have been seen so far in 2020.
Wednesday's top analyst upgrades, downgrades and initiations included Casper Sleep, CME, Deere, Domino's Pizza, Home Depot, Nike, RealReal, Salesforce.com, SolarEdge Technologies, Sunrun and Walt...
Tuesday's top analyst upgrades, downgrades and initiations included Aurora Cannabis, Biogen, EverQuote, Micron Technology, Nio, Nvidia, Palo Alto Networks, Tandem Diabetes Care, Tesla and Wix.com.
Why Credit Suisse believes that this round of quarterly biotech earnings could prove to be a catalyst for 2020.
Christmas Eve's top analyst upgrades, downgrades and initiations included Amgen, Apple, Builder FirstSource, CarMax, Dominion Energy, FedEx, Nike, Regeneron Pharmaceuticals and Sarpeta Therapeutics.
24/7 Wall St. has identified 10 stocks that have risen 1,000% or more since the last trading day of 2009.
Tuesday's top analyst upgrades, downgrades and initiations included Albermarle, Amgen, Applied Materials, Biogen, CRISPR Therapeutics, CrowdStrike, CSX, Kroger, Slack, Teva Pharmaceutical and Xerox.
Wednesday's top analyst upgrades, downgrades and initiations included Altice USA, CenturyLink, Cigna, Emerson Electric, Foot Locker, Groupon, Lululemon Athletica, Nike, State Street and Walt Disney.
One sector that has avoided much of the current trade and recession fear turmoil is health care, and especially the biotech companies. The four top stocks have gigantic implied upside.
Of the 40 worst performers in the S&P 500 so far in 2019, 11 are tied to oil and gas, 10 tied mostly to retailing of apparel and accessories, and six are tied to pharmaceuticals and biotech.
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
Stocks were indicated to open higher on Tuesday after a small gain in the Dow and S&P 500 on Monday. It may be the summer, but investors need to be considering how they want their portfolios and...
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how much they are lagging...
Alnylam Pharma and Regeneron Pharma shares dipped on Monday despite announcing a collaboration to discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases.
In an incredible move for adolescent patients 12 to 17 years of age, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for with moderate-to-severe atopic dermatitis.